Zacks: Analysts Set $24.50 Target Price for Mast Therapeutics, Inc. (SVRA)
Mast Therapeutics, Inc. (NASDAQ:SVRA) has received an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation. Mast Therapeutics’ rating score has improved by 50% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 12-month consensus target price of $24.50 for the company and are predicting that the company will post ($0.40) EPS for the current quarter, according to Zacks. Zacks has also assigned Mast Therapeutics an industry rank of 159 out of 265 based on the ratings given to its competitors.
Several equities analysts have recently commented on SVRA shares. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 price objective on shares of Mast Therapeutics in a research note on Monday, July 17th. Zacks Investment Research raised shares of Mast Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research note on Friday, September 8th. Jefferies Group LLC began coverage on shares of Mast Therapeutics in a research note on Friday, September 22nd. They issued a “buy” rating and a $20.00 price target for the company. JMP Securities began coverage on shares of Mast Therapeutics in a research note on Monday, September 11th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Roth Capital reissued a “buy” rating and issued a $40.00 price target on shares of Mast Therapeutics in a research note on Wednesday, September 27th.
Shares of Mast Therapeutics (SVRA) opened at 8.49 on Monday. The firm’s market cap is $205.48 million. The firm’s 50-day moving average is $8.59 and its 200-day moving average is $6.65. Mast Therapeutics has a 12-month low of $4.60 and a 12-month high of $16.23.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.